Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, K.
Right arrow Articles by Hirohata, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, K.
Right arrow Articles by Hirohata, T.
[Cancer Research 60, 5106-5110, September 15, 2000]
© 2000 American Association for Cancer Research

Regular Articles

Serum Testosterone:Estradiol Ratio and the Development of Hepatocellular Carcinoma among Male Cirrhotic Patients1

Keitaro Tanaka2, Hironori Sakai, Makoto Hashizume and Tomio Hirohata

Departments of Preventive Medicine [K. T.] and Disaster and Emergency Medicine [M. H.], Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582; Division of Gastroenterology, National Kyushu Medical Center Hospital, Fukuoka 810-0065 [H. S.]; and Nakamura Gakuen University, Fukuoka 814-0198 [T. H.], Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The reason for the large male predominance in the occurrence of hepatocellular carcinoma (HCC) remains unknown, and sex hormones may contribute to this phenomenon. We examined possible associations of serum levels of testosterone, free testosterone, estradiol, sex hormone binding globulin, and testosterone:estradiol ratio (T:E2 ratio) with HCC development in a follow-up study of 46 Japanese male patients with liver cirrhosis predominantly of hepatitis C virus origin (76%). Serum samples were collected between December 1985 and December 1987, and the patients were completely followed until the end of 1995 for an average of 5.1 years. During the follow-up period, 20 patients (43%) developed HCC. Univariate analysis demonstrated that serum T:E2 ratio and testosterone were significant predictors of HCC; the hazard ratios (and 95% confidence intervals) in the middle and upper tertiles relative to the lower tertile were 2.0 (0.5–7.6) and 4.0 (1.1–14.6; P trend = 0.03) for T:E2 ratio and 0.8 (0.2–3.1) and 2.9 (1.0–8.5; P trend = 0.05) for testosterone. Adjustment for age, serum albumin, hepatitis virus markers, and other clinicobiological variables substantially increased the corresponding hazard ratios. In multivariate analysis, serum free testosterone appeared to be associated with increased risk, yet independent associations with estradiol and sex hormone binding globulin were not evident. These results indicate that elevated serum testosterone, together with decreased serum estrogens, may promote the development of HCC in cirrhosis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
HCC3 develops much more frequently in men than in women. At least 2–3-fold male predominance in the incidence of primary liver cancer, largely HCC, is universally observed (1) . The reason for this large sex difference remains to be elucidated. As for the situation in Japan, the prevalence of hepatitis C virus infection, the most important etiological factor of HCC in this country (2, 3, 4) , has been shown to be similar or only slightly different between both sexes according to blood donor data (3 , 5 , 6) . Other potential risk factors more common in Japanese men than women comprise alcohol consumption and cigarette smoking. However, heavy drinking was estimated to account for only 13% of male HCC occurrences in our previous case-control study in a high risk area of Japan (7) , and the causal link between smoking and HCC still remains uncertain (7) . These findings necessarily raise the possibility that sex hormones may be involved in the etiology of HCC.

Numerous animal experiments have underscored a promoting role of testosterone in murine hepatocarcinogenesis (8, 9, 10, 11, 12, 13) , although the role of estrogens remains in dispute (13, 14, 15, 16, 17, 18) . In contrast, analytic epidemiological data on sex hormones and HCC have been sparse and controversial, except for the link between oral contraceptive use and HCC (19) . Yu and Chen (20) first described a positive association between serum testosterone level and risk of HCC in a nested case-control study in Taiwan, where hepatitis B virus represents a major causative agent. This positive association was replicated in a subsequent nested case-control study in Shanghai (21) , but the association was confounded by chronic hepatitis B virus infection, which was positively related to serum testosterone level. In a French follow-up study of male patients with LC mostly attributable to alcohol abuse (22) , neither testosterone nor estradiol level in serum was predictive of HCC occurrence. Because of the clear need for further studies on this issue, we performed a follow-up study of male cirrhotic patients mainly of hepatitis C virus origin, taking into account the effects of other clinicobiological measurements that are possibly associated with both serum hormone levels and HCC risk.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Subjects.
The details of the subjects and the methods have been described elsewhere (23) . In brief, a total of 100 Japanese patients with LC who were attending or were admitted to the Third Department of Internal Medicine and the Second Department of Surgery at Kyushu University Hospital between December 1985 and December 1987 were recruited, as one of patient groups in case-control studies of HCC and LC, according to the following selection criteria: (a) without evidence of HCC based on ultrasonography, computed tomography, and/or serum {alpha}-fetoprotein level; (b) 40–69 years of age; (c) residents in Fukuoka or Saga prefecture (adjacent to Fukuoka prefecture); and (d) of Japanese nationality. In addition, patients with special forms of LC (primary or secondary biliary cirrhosis and cirrhosis attributable to autoimmune hepatitis, parasitosis, congestive heart failure, or metabolic disorders) were excluded. Patients were regarded as having been enrolled when an interview survey on their life styles, including a past history of alcohol drinking, was successfully conducted by a trained interviewer. Among the 100 patients, sera from 75 patients (48 men and 27 women) were collected on the date of enrollment for outpatients or during admission for inpatients. Of the 75 patients, 48 men were followed in this study. In data analysis, we further eliminated 2 men whose follow-up period was <=6 months as described below, leaving 46 patients (27 patients from the medicine department and 19 patients from the surgery department; 35 outpatients and 11 inpatients; 44 residents in Fukuoka prefecture and 2 residents in Saga prefecture). The median age was 56 years. The diagnosis of LC was based on histology for 17 patients (37%), laparoscopy for 8 patients (17%), and evident clinical signs (e.g., ascites and esophageal varices) and laboratory/imaging findings for 21 patients (46%). The causes of LC were considered to be hepatitis C virus infection (n = 26), both hepatitis C virus infection and alcohol (ethanol use >=80 ml/day for >=10 years; n = 8), hepatitis B virus infection (n = 4), both viral infections (n = 1), alcohol (n = 4), and cryptogenic (n = 3). According to the Child-Turcotte stage, 23 patients (50%) were classified as stage A at enrollment, 18 patients (39%) as stage B, and 5 patients (11%) as stage C. None of the 46 patients had received IFN therapy during follow-up.

Follow-Up.
The end point in this study was defined as the development of HCC as a final diagnosis >6 months after enrollment. The follow-up began on the date of enrollment and finished upon the diagnosis of the end point, death from other causes, loss to follow-up, or December 31, 1995, whichever came first. For 33 patients who had been attending the cooperating departments or relevant hospitals until the last date of follow-up, serum {alpha}-fetoprotein level had been measured every month, and ultrasound and/or computed tomography examination of the liver had been performed every 3–6 months, followed by arteriography and/or liver biopsy if HCC occurrence had been highly suspected. For the remaining 15 patients, we investigated the vital status as of December 31, 1995 through municipal public offices retaining permanent address records ("koseki" in Japanese). Nine patients were dead, and we retrospectively determined whether they had developed HCC by contacting attending physicians or their colleagues. For five of six survivors, we could locate current attending physicians to obtain follow-up data. One patient who had not been attending any hospital visited the cooperating medicine department after telephone contact, and ultrasonography revealed no evidence of HCC. Consequently, complete follow-up information was obtained for all 48 patients. According to the definition of the end point, 2 patients who had died or developed HCC within the initial 6 months were excluded. Of the 46 patients used in this study, 20 (43%) had developed HCC as the end point; 4 were diagnosed from histology, 12 from angiography, and 4 from computed tomography and/or ultrasonography; all of the last 4 patients had subsequently died of the disease. The average (or median) follow-up period was 5.1 (4.4) years, with the 5- and 10-year cumulative survival rates of 61 and 17%, respectively.

Laboratory Tests.
Serum levels of albumin, aspartate aminotransferase, and {alpha}-fetoprotein at enrollment or, if unavailable, within 1 month before or after enrollment, as well as the serostatus of hepatitis B surface antigen determined by a reverse passive hemagglutination method (Auscell; Abbott, Chicago, IL) were abstracted from medical records.

Serum specimens were frozen at -70°C until tested for hepatitis C virus markers and hormonal measurements. Antibodies to hepatitis C virus were determined by a second generation immunoradiometric assay (Ortho, Raritan, NJ). Positive results in this assay were further confirmed by a second generation recombinant immunoblot assay (Chiron, Emeryville, CA). In addition, all sera were tested for the presence of hepatitis C virus-RNA by reverse transcription polymerase reaction (Amplicor HCV; Roche Diagnostic Systems, Basel, Switzerland). Reactive results by the immunoblot assay, or indeterminate results by the assay with the presence of hepatitis C virus-RNA, were regarded as positive for antibodies to hepatitis C virus. Serum concentrations of testosterone, free testosterone, and estradiol were determined by specific 125I-radioimmunoassays (Coat-A-Count; DPC, Los Angeles, LA). SHBG was examined by a time-resolved fluoroimmunoassay (Delfia SHBG; Wallac Oy, Turku, Finland).

Statistical Analysis.
Serum T:E2 ratio was calculated as testosterone in ng/ml divided by estradiol in ng/ml, although otherwise the estradiol level was expressed in pg/ml. Each hormone-related variable was categorized at tertiles. The cumulative incidence of HCC was calculated by the method of Kaplan and Meier (24) . The difference among the incidence curves was evaluated by a log-rank test. Cox proportional hazards models were used to estimate the HRs and their 95% CIs of developing HCC for each hormonal variable with adjustment for potential confounders including age (in years), years since LC diagnosis (<2 versus >=2), department (internal medicine versus surgery), hospitalization status (inpatient versus outpatient), heavy drinking history (alcohol consumption >=80 ml/day for >=10 years versus less), serum levels of albumin (g/dl), aspartate aminotransferase [<72.5 units/l (median value among the study subjects) versus >=72.5 units/l], and {alpha}-fetoprotein [<20 ng/ml (upper normal limit) versus >=20 ng/ml], the serostatus of hepatitis B surface antigen and antibodies to hepatitis C virus, and other hormonal parameters (tertile classification; Ref. 25 ). The Ps quoted were two-tailed, and those <0.05 were considered statistically significant. Statistical analyses were performed with the SAS (SAS Institute Inc., Cary, NC) and Stata (StataCorp., College Station, TX) statistical packages.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Average concentrations (±SD) of serum testosterone, free testosterone, estradiol, and SHBG were 5.4 ± 2.1 ng/ml, 10.5 ± 4.4 pg/ml, 28.0 ± 12.7 pg/ml, and 83.5 ± 29.4 nM/l, respectively. Serum T:E2 ratio ranged from 31 to 722 with an average (±SD) of 226 ± 127.

Table 1Citation shows the cumulative 5-year HCC incidence and the crude HRs according to the tertile classification of each hormonal measurement. Raised levels of testosterone and T:E2 ratio were associated with increased risk (P = 0.03 and 0.06, respectively, by log-rank tests), and the dose-response relation was clearest for T:E2 ratio (Table 1Citation and Fig. 1Citation ); increased risk was observed both for patients with less than the median length (4.4 years) of follow-up [HR (and 95% CI) in the upper tertile relative to the middle and lower tertiles: 2.2 (0.7–6.8) for testosterone and 2.0 (0.7–6.0) for T:E2 ratio] and for patients with >=4.4 years of follow-up [corresponding HRs: 4.1 (0.8–20.5) for testosterone and 3.5 (0.7–17.3) for T:E2 ratio]. Elevated risk was also noted for SHBG, yet the association did not reach statistical significance. Unlike testosterone, free testosterone was associated with insignificantly decreased risk. The estradiol level was not predictive of HCC risk in univariate analysis.


View this table:
[in this window]
[in a new window]
  		Table 1 HCC incidence and associated HRs according to serum levels of hormonal measurements among 46 male cirrhotic patients

 


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1. Cumulative incidence of HCC according to the tertile classification of serum T:E2 ratio among 46 male cirrhotic patients. The three levels are indicated as follows: Low, <162; Middle, 162–245; High, >=246. P for the difference between the incidence curves was 0.06 by a log-rank test, and that for linear trend was 0.03 by the Cox proportional hazards model as shown in Table 1Citation .

 
Age adjustment had a little influence on the HRs shown in Table 1Citation (data not shown). However, some of those estimates were materially changed by additional adjustment for serum albumin level (model 1 in Table 2Citation ), which was strongly inversely associated with HCC risk as reported previously (23) , and was also correlated positively with testosterone [Spearman rank correlation coefficient (r) = 0.16], free testosterone (r = 0.50), and T:E2 ratio (r = 0.20) and inversely with estradiol (r = -0.20) and SHBG (r = -0.25); the HRs for testosterone and T:E2 ratio substantially increased, and the inverse association with free testosterone observed in crude analysis disappeared.


View this table:
[in this window]
[in a new window]
  		Table 2 Adjusted HRs (and 95% CIs) for HCC development according to serum levels of hormonal measurements among 46 male cirrhotic patients

 
When the effects of other clinicobiological variables were further controlled for (model 2 in Table 2Citation ), the positive associations with testosterone and T:E2 ratio became even stronger, but with statistical instability as indicated by wide CIs, and an upward gradient in HCC risk with increasing free testosterone emerged. Finally, controlling additionally for hormonal measurements (model 3 in Table 2Citation ) did not essentially alter the positive associations with testosterone, free testosterone, and T:E2 ratio. In this final model, the upper tertile for either estradiol or SHBG appeared to present lower risk than did the corresponding lower tertile, although not statistically significant.

A subgroup analysis of patients who tested seropositive for antibody to hepatitis C virus but seronegative for hepatitis B surface antigen (n = 34) gave similar HRs for serum testosterone and T:E2 ratio as those in Tables 1Citation and 2Citation . For example, the age- and albumin-adjusted HRs (and 95% CI) in the middle and upper tertiles as compared with the lower tertile were 1.3 (0.2–6.6) and 4.2 (0.9–19.5) for testosterone (P for trend = 0.04) and 3.1 (0.8–12.6) and 5.5 (1.3–23.0) for T:E2 ratio (P for trend = 0.02). For other etiological categories, the sample size (5 patients seropositive for hepatitis B surface antigen and 7 patients seronegative for both viral markers) was too small to perform separate analyses.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our results indicate that elevated levels of serum T:E2 ratio and testosterone are predictive of HCC risk among male cirrhotic patients. Of particular note was that the positive associations were substantially strengthened after controlling for other clinicobiological parameters including serum albumin level, one of the liver function measurements that reflect the severity of cirrhosis. Previous clinical investigations found that serum estradiol (or estrone):testosterone ratio, the reciprocal of our variable, was higher in patients with HCC and LC than in patients with LC alone or control subjects, suggesting that hormonal imbalance as manifested by elevated estradiol and/or decreased testosterone levels might be involved in hepatocarcinogenesis (26, 27, 28, 29) . However, such a finding can be attributed to the advanced severity of LC among HCC patients, which is well recognized to reduce serum testosterone and to elevate serum estrogens (30) .

Analytic epidemiological data on androgens in causation of HCC remain scanty, although several HCC cases after anabolic androgenic steroid administration (31, 32, 33, 34) have been documented. In a nested case-control study in Taiwan where hepatitis B virus infection is a major cause of HCC, Yu and Chen (20) observed that the adjusted relative risk for HCC among men in the upper tertile of serum testosterone was 4.1 (95% CI, 1.3–13.2) compared with those in the middle and lower tertiles. A subsequent nested case-control study in Shanghai confirmed a similar positive association, but the association became no more evident after adjustment for serum hepatitis B surface antigen status (21) . Both studies evaluated serum testosterone alone, and no consideration was given to estrogens, free testosterone, or SHBG. Among our cirrhotic patients predominantly of hepatitis C virus origin (76%), increased risk was observed for elevated serum testosterone levels but more evidently for raised T:E2 ratio. It remains to be elucidated whether our finding holds true in other settings where hepatitis B virus or alcohol represents a predominant cause of LC. In a French follow-up study of 101 male cirrhotic patients (22) , serum SHBG, but neither testosterone nor estradiol, had a predictive value for HCC occurrence. The authors mentioned that the results in the first Chinese study (20) could not be extrapolated to older Western patients with cirrhosis mainly from alcoholic origin similar to those included in their study. In this study, SHBG appeared to be associated with increased risk in univariate analysis but not in fully adjusted analysis.

Voluminous experimental evidence suggests that androgens have promoting activity in hepatocarcinogenesis. Spontaneous hepatomas or preneoplastic liver lesions occur more frequently in male rodents than in females (8 , 35) . Male mice transgenic for hepatitis B virus (36) or hepatitis C virus (37) are more likely to spontaneously develop HCC than female counterparts. Male rodents are more susceptible to hepatocarcinogens (9 , 11 , 13 , 38, 39, 40) , and castration protects them against liver tumor induction (9 , 10 , 38, 39, 40) or the growth of enzyme-altered hepatic foci (12 , 13) whereas simultaneous administration of testosterone restores the susceptibility (9 , 10 , 12) . In castrated female rodents, testosterone administration also increases the growth of chemically induced preneoplastic liver lesions (11 , 13) . Antiandrogen treatment (e.g., chlormadinone acetate) exerts an inhibitory effect on chemical hepatocarcinogenesis in male rats (41) . Finally, androgen receptors are, more frequently and at a higher concentration, detected in human HCC than in the surrounding cirrhotic parenchyma (42 , 43) .

Conversely, the role of estrogens in the pathogenesis of HCC remains controversial. Initial clinical observations of benign and even malignant hepatocellular tumors in women taking oral contraceptives (44, 45, 46) prompted researchers to perform relevant animal experiments. Early data demonstrated promoting effects of estrogens, such as estradiol-17-phenylpropionate and estradiol benzoate (15) , mestranol (16) , and ethinyl estradiol (17) , on the development of hepatic foci, hepatic nodules, or HCC in rats, following the administration of hepatocarcinogens. However, several subsequent studies provided almost opposite findings. Mishkin et al. (14) observed an unexpected inhibitory effect of 17ß-estradiol and tamoxifen against liver tumor development induced chemically in rats. Yager et al. (18) showed that chronic treatment of ethinyl estradiol to rats caused an inhibition of regenerative liver growth, after an initial transient increase in liver growth. Shimizu et al. (13) also demonstrated a suppressive effect of estradiol valerate on glutathione S-transferase-positive foci in rats. The discrepancy across studies may result partly from the differences in sex steroid compounds used and the administration dose of each compound. Estrogen receptors have been detected in both human HCC and the surrounding liver tissue but usually at a lower concentration in the former (43 , 47, 48, 49) . In addition, estrogen receptors mutated in the hormone-binding domain have been implicated in a carcinogenic process among male cirrhotic patients through the escape from hormonal control (50) .

Although a significant independent association with serum estradiol was not evident in this study, the fully adjusted analysis revealed a risk reduction (HR, 0.4) in the upper tertile of the estradiol level, and the T:E2 ratio was found to be the best predictor of HCC among hormonal measurements. This suggests that elevated serum estradiol may confer a somewhat decreased risk of HCC, although the role of serum testosterone appeared predominant. The causal link between oral contraceptive use and HCC has been established in areas with a low prevalence of hepatitis virus infection (19) , yet such evidence cannot be extrapolated to the situation where the role of endogenous estrogens within almost physiological levels is examined among male patients with LC associated with hepatitis virus infection. It is conceivable that estrogens may exert both promoting and inhibitory effects on human hepatocarcinogenesis, depending on the dose, type, endogenous or exogenous origin, sex, and presence or absence of hepatitis virus infection.

To our knowledge, no other studies have examined serum T:E2 ratio as a predictor of HCC development in cirrhosis. Because this study was small and had less precision to estimate the associated HRs, larger studies are clearly required to consolidate our findings.


   ACKNOWLEDGMENTS
 
We are grateful to T. Hayashi for interviewing study subjects and to the staff members of the Third Department of Internal Medicine and the Second Department of Surgery, Faculty of Medicine, Kyushu University, for their kind cooperation.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grant 08670395 from the Ministry of Education, Science, Sports and Culture, Japan. Back

2 To whom requests for reprints should be addressed, at the Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-6112; Fax: 81-92-642-6115; E-mail: ktanaka{at}phealth.med.kyushu-u.ac.jp Back

3 The abbreviations used are: HCC, hepatocellular carcinoma; LC, liver cirrhosis; SHBG, sex hormone binding globulin; T:E2 ratio, testosterone to estradiol ratio; HR, hazard ratio; CI, confidence interval. Back

Received 1/ 3/00. Accepted 7/20/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. International Agency for Research on Cancer. Cancer Incidence in Five Continents Volume VII. Lyon: IARC, 1997.
  2. Nishioka K., Watanabe J., Furuta S., Tanaka E., Iino S., Suzuki H., Tsuji T., Yano M., Kuo G., Choo Q. L., Houghton M., Oda T. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer (Phila.), 67: 429-433, 1991.[Medline]
  3. Tanaka K., Hirohata T., Koga S., Sugimachi K., Kanematsu T., Ohryohji F., Nawata H., Ishibashi H., Maeda Y., Kiyokawa H., Tokunaga K., Irita Y., Takeshita S., Arase Y., Nishino N. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res., 51: 2842-2847, 1991.[Abstract/Free Full Text]
  4. Tanaka K., Ikematsu H., Hirohata T., Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J. Natl. Cancer Inst., 88: 742-746, 1996.[Abstract/Free Full Text]
  5. Tanaka H., Hiyama T., Tsukuma H., Okubo Y., Yamano H., Kitada A., Fujimoto I. Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka. Japan. Cancer Causes Control, 5: 409-413, 1994.
  6. Watanabe J., Minegishi K., Mitsumori T., Ishifuji M., Oguchi T., Ueda M., Tokunaga E., Tanaka E., Kiyosawa K., Furuta S., Katayama T., Kuo G., Choo Q. L., Houghton M., Nishioka K. Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang., 59: 86-88, 1990.[Medline]
  7. Tanaka K., Hirohata T., Takeshita S., Hirohata I., Koga S., Sugimachi K., Kanematsu T., Ohryohji F., Ishibashi H. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int. J. Cancer, 51: 509-514, 1992.[Medline]
  8. Agnew L. R. C., Gardner W. U. The incidence of spontaneous hepatomas in C3H, C3H (low milk factor), and CBA mice and the effect of estrogen and androgen on the occurrence of these tumors in C3H mice. Cancer Res., 12: 757-761, 1952.
  9. Firminger H. I., Reuber M. D. Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in A x C rats fed N-2-fluorenyldiacetamide. J. Natl. Cancer Inst., 27: 559-595, 1961.
  10. Reuber M. D. Influence of hormones on N-2-fluorenyldiacetamide-induced hyperplastic hepatic nodules in rats. J. Natl. Cancer Inst., 43: 445-452, 1969.
  11. Moore M. R., Drinkwater N. R., Miller E. C., Miller J. A., Pitot H. C. Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res., 41: 1585-1593, 1981.[Abstract/Free Full Text]
  12. Lindhe B., Porsch-Hallstrom I., Gustafsson J. A., Blanck A. Effects of neonatal and adult castration and of testosterone substitution in male rats on growth of enzyme-altered hepatic foci in the resistant hepatocyte model. Cancer Res., 50: 2679-2682, 1990.[Abstract/Free Full Text]
  13. Shimizu I., Yasuda M., Mizobuchi Y., Ma Y. R., Liu F., Shiba M., Horie T., Ito S. Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats. Gut, 42: 112-119, 1998.[Abstract/Free Full Text]
  14. Mishkin S. Y., Farber E., Ho R. K., Mulay S., Mishkin S. Evidence for the hormone dependency of hepatic hyperplastic nodules: inhibition of malignant transformation after exogenous 17 ß-estradiol and tamoxifen. Hepatology, 3: 308-316, 1983.[Medline]
  15. Taper H. S. The effect of estradiol-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in ovariectomized female rats. Cancer (Phila.), 42: 462-467, 1978.[Medline]
  16. Yager J. D., Jr., Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res., 40: 3680-3685, 1980.[Abstract/Free Full Text]
  17. Cameron R. G., Imaida K., Tsuda H., Ito N. Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res., 42: 2426-2428, 1982.[Abstract/Free Full Text]
  18. Yager J. D., Zurlo J., Sewall C. H., Lucier G. W., He H. Growth stimulation followed by growth inhibition in livers of female rats treated with ethinyl estradiol. Carcinogenesis (Lond.), 15: 2117-2123, 1994.[Abstract/Free Full Text]
  19. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 72, Hormonal Contraception and Post-Menopausal Hormonal Therapy, pp. 49–338. Lyon: IARC, 1999.
  20. Yu M. W., Chen C. J. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res., 53: 790-794, 1993.[Abstract/Free Full Text]
  21. Yuan J. M., Ross R. K., Stanczyk F. Z., Govindarajan S., Gao Y. T., Henderson B. E., Yu M. C. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int. J. Cancer, 63: 491-493, 1995.[Medline]
  22. Ganne-Carrie N., Chastang C., Uzzan B., Pateron D., Trinchet J. C., Perret G., Beaugrand M. Predictive value of serum sex hormone binding globulin for the occurrence of hepatocellular carcinoma in male patients with cirrhosis. J. Hepatol., 26: 96-102, 1997.[Medline]
  23. Tanaka K., Sakai H., Hashizume M., Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn. J. Cancer Res., 89: 1241-1250, 1998.[Medline]
  24. Kaplan E. L., Meier P. Nonparametric estimation for incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
  25. SAS Institute, Inc. SAS/STAT Software. Changes and Enhancements through Release 6.11, the PHREG Procedure, pp. 807–884. Cary, NC: SAS Institute, Inc., 1996.
  26. Farinati F., De Maria N., Marafin C., Fagiuoli S., Della Libera G., Naccarato R. Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor?. Eur. J. Gastroenterol. Hepatol., 7: 145-150, 1995.[Medline]
  27. Nagasue N., Ogawa Y., Yukaya H., Ohta N., Ito A. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology, 88: 768-772, 1985.[Medline]
  28. Montalto G., Miceli M. D., Soresi M., Amodio R., Carroccio A., Cartabellotta A., Castagnetta L. Sex hormones in patients with liver cirrhosis and hepatocellular carcinoma. Oncol. Rep., 4: 173-176, 1997.
  29. Guechot J., Peigney N., Ballet F., Vaubourdolle M., Giboudeau J., Poupon R. Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer (Phila.), 62: 760-762, 1988.[Medline]
  30. Johnson P. J. Sex hormones and the liver. Clin. Sci., 66: 369-376, 1984.[Medline]
  31. Bernstein M. S., Hunter R. L., Yachnin S. Hepatoma and peliosis hepatitis developing in a patient with Fanconi’s anemia. N. Engl. J. Med., 284: 1135-1136, 1971.
  32. Johnson F. L., Lerner K. G., Siegel M., Feagler J. R., Majerus P. W., Hartmann J. R., Thomas E. D. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet, 2: 1273-1276, 1972.[Medline]
  33. Farrell G. C., Joshua D. E., Uren R. F., Baird P. J., Perkins K. W., Kronenberg H. Androgen-induced hepatoma. Lancet, 1: 430-432, 1975.[Medline]
  34. Westaby D., Portmann B., Williams R. Androgen related primary hepatic tumors in non-Fanconi patients. Cancer (Phila.), 51: 1947-1952, 1983.[Medline]
  35. Sawaki M., Enomoto K., Takahashi H., Nakajima Y., Mori M. Phenotype of preneoplastic and neoplastic liver lesions during spontaneous liver carcinogenesis of LEC rats. Carcinogenesis (Lond.), 11: 1857-1861, 1990.[Abstract/Free Full Text]
  36. Kim C. M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (Lond.), 351: 317-320, 1991.[Medline]
  37. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., Matsuura Y., Kimura S., Miyamura T., Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med., 4: 1065-1067, 1998.[Medline]
  38. Vesselinovitch S. D., Mihailovich N. The effect of gonadectomy on the development of hepatomas induced by urethan. Cancer Res., 27: 1788-1791, 1967.
  39. Vesselinovitch S. D., Itze L., Mihailovich N., Rao K. V. Modifying role of partial hepatectomy and gonadectomy in ethylnitrosourea-induced hepatocarcinogenesis. Cancer Res., 40: 1538-1542, 1980.[Abstract/Free Full Text]
  40. Toh Y. C. Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis (Lond.), 2: 1219-1221, 1981.[Abstract/Free Full Text]
  41. Matsuura B., Taniguchi Y., Ohta Y. Effect of antiandrogen treatment on chemical hepatocarcinogenesis in rats. J. Hepatol., 21: 187-193, 1994.[Medline]
  42. Nagasue N., Ito A., Yukaya H., Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology, 89: 643-647, 1985.[Medline]
  43. Ohnishi S., Murakami T., Moriyama T., Mitamura K., Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology, 6: 440-443, 1986.[Medline]
  44. Baum J. K., Bookstein J. J., Holtz F., Klein E. W. Possible association between benign hepatomas and oral contraceptives. Lancet, 2: 926-929, 1973.[Medline]
  45. Davis M., Portmann B., Searle M., Wright R., Williams R. Histological evidence of carcinoma in a hepatic tumour associated with oral contraceptives. Br. Med. J., 4: 496-498, 1975.
  46. Christopherson W. M., Mays E. T., Barrows G. H. Liver tumors in women on contraceptive steroids. Obstet. Gynecol., 46: 221-223, 1975.[Abstract/Free Full Text]
  47. Friedman M. A., Demanes D. J., Hoffman P. G., Jr. Hepatomas: hormone receptors and therapy. Am. J. Med., 73: 362-366, 1982.[Medline]
  48. Nagasue N., Kohno H., Chang Y. C., Hayashi T., Utsumi Y., Nakamura T., Yukaya H. Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. Cancer (Phila.), 63: 112-116, 1989.[Medline]
  49. Eagon P. K., Francavilla A., DiLeo A., Elm M. S., Gennari L., Mazzaferro V., Colella G., Van Thiel D. H., Strazl T. E. Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig. Dis. Sci., 36: 1303-1308, 1991.[Medline]
  50. Villa E., Camellini L., Dugani A., Zucchi F., Grottola A., Merighi A., Buttafoco P., Losi L., Manenti F. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res., 55: 498-500, 1995.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
F. Trevisani, M.C. Cantarini, J.R. Wands, and M. Bernardi
Recent advances in the natural history of hepatocellular carcinoma
Carcinogenesis, July 1, 2008; 29(7): 1299 - 1305.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
S. R. Boutin, A. B. Rogers, Zeli Shen, R. C. Fry, J. A. Love, P. R. Nambiar, S. Suerbaum, and J. G. Fox
Hepatic Temporal Gene Expression Profiling in Helicobacter hepaticus-Infected A/JCr Mice
Toxicol Pathol, October 1, 2004; 32(6): 678 - 693.
[Abstract] [PDF]

Home page
 GutHome page
R Sato, C Maesawa, K Fujisawa, K Wada, K Oikawa, Y Takikawa, K Suzuki, H Oikawa, K Ishikawa, and T Masuda
Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis
Gut, July 1, 2004; 53(7): 1001 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. A. M. Castagnetta, B. Agostara, G. Montalto, L. Polito, I. Campisi, A. Saetta, T. Itoh, B. Yu, S. Chen, and G. Carruba
Local Estrogen Formation by Nontumoral, Cirrhotic, and Malignant Human Liver Tissues and Cells
Cancer Res., August 15, 2003; 63(16): 5041 - 5045.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen
Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men
J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, K.
Right arrow Articles by Hirohata, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, K.
Right arrow Articles by Hirohata, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online